Omnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of “Buy” by Brokerages

Posted by Francis Steltz on Jul 7th, 2026

Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) has earned a consensus recommendation of “Buy” from the nine research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $59.8571.

A number of research firms have recently weighed in on OMCL. UBS Group set a $60.00 price target on Omnicell and gave the stock a “buy” rating in a report on Friday, March 13th. KeyCorp upped their price objective on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Wells Fargo & Company increased their price objective on shares of Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th.

Check Out Our Latest Stock Analysis on Omnicell

Insider Activity

In other news, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the transaction, the executive vice president directly owned 112,783 shares in the company, valued at approximately $4,874,481.26. This trade represents a 4.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president directly owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This represents a 1.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Omnicell

Several hedge funds have recently bought and sold shares of OMCL. Wellington Management Group LLP lifted its holdings in shares of Omnicell by 156.4% during the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after buying an additional 1,265,818 shares during the last quarter. Millennium Management LLC bought a new position in Omnicell in the 3rd quarter worth $25,625,000. First Light Asset Management LLC bought a new position in shares of Omnicell in the first quarter worth about $16,351,000. Boston Partners acquired a new position in shares of Omnicell during the fourth quarter worth approximately $20,805,000. Finally, WCM Investment Management LLC acquired a new position in Omnicell during the 1st quarter valued at $9,783,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Performance

Omnicell stock traded down $0.49 during mid-day trading on Thursday, reaching $44.74. 69,958 shares of the company were exchanged, compared to its average volume of 635,409. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.29 and a current ratio of 1.50. The firm’s 50-day simple moving average is $41.92 and its two-hundred day simple moving average is $41.52. Omnicell has a twelve month low of $26.84 and a twelve month high of $55.00. The firm has a market cap of $2.04 billion, a PE ratio of 101.70, a price-to-earnings-growth ratio of 1.11 and a beta of 0.96.

Omnicell (NASDAQ:OMCL – Get Free Report) last released its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter in the previous year, the firm posted $0.26 EPS. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Equities analysts predict that Omnicell will post 1.31 earnings per share for the current fiscal year.

About Omnicell

(Get Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.